Literature DB >> 16247771

Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.

Khalid Iqbal1, Michael Flory, Sabiha Khatoon, Hilkka Soininen, Tuula Pirttila, Maarit Lehtovirta, Irina Alafuzoff, Kaj Blennow, Niels Andreasen, Eugeen Vanmechelen, Inge Grundke-Iqbal.   

Abstract

Alzheimer's disease, the most common cause of dementia, is multifactorial and heterogeneous; its diagnosis remains probable. We postulated that more than one disease mechanism yielded Alzheimer's histopathology, and that subgroups of the disease might be identified by the cerebrospinal fluid (CSF) levels of proteins associated with senile (neuritic) plaques and neurofibrillary tangles. We immunoassayed levels of tau, ubiquitin, and Abeta(1-42) in retrospectively collected CSF samples of 468 clinically diagnosed Alzheimer's disease patients (N = 353) or non-Alzheimer's subjects (N = 115). Latent profile analysis assigned each subject to a cluster based on the levels of these molecular markers. Alzheimer's disease was subdivided into at least five subgroups based on CSF levels of Abeta(1-42), tau, and ubiquitin; each subgroup presented a different clinical profile. These subgroups, which can be identified by CSF analysis, might benefit differently from different therapeutic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16247771     DOI: 10.1002/ana.20639

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  47 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.

Authors:  Norbert Zilka; Miroslava Korenova; Branislav Kovacech; Khalid Iqbal; Michal Novak
Journal:  Acta Neuropathol       Date:  2010-04-09       Impact factor: 17.088

3.  The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Authors:  Sebastiaan Engelborghs; Nathalie Le Bastard
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

4.  Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification.

Authors:  Hidenaga Yamamori; Sabiha Khatoon; Inge Grundke-Iqbal; Kaj Blennow; Michael Ewers; Harald Hampel; Khalid Iqbal
Journal:  Neurosci Lett       Date:  2007-03-14       Impact factor: 3.046

Review 5.  Transdermal delivery of treatment for Alzheimer's disease: development, clinical performance and future prospects.

Authors:  Agnes L F Chan; Yie W Chien; Shun Jin Lin
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 6.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  SOCIAL ENVIRONMENTAL RISK AND PROTECTION: A TYPOLOGY WITH IMPLICATIONS FOR PRACTICE IN ELEMENTARY SCHOOLS.

Authors:  Natasha K Bowen; Jung-Sook Lee; Bridget E Weller
Journal:  Child Sch       Date:  2007

8.  PUTATIVE CSF PROTEIN BIOMARKER CANDIDATES FOR AMNESTIC MILD COGNITIVE IMPAIRMENT.

Authors:  Scott E Counts; Elliott J Mufson
Journal:  Transl Neurosci       Date:  2010-03-01       Impact factor: 1.757

Review 9.  Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease.

Authors:  Khalid Iqbal; M Omar Chohan; Inge Grundke-Iqbal
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 10.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.